Browse

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.

Among the affected positions, which the White House estimates to be 8,000, are high-level officials who oversee research grants from the NIH.

Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.